pyrazines has been researched along with quinazolines in 84 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (3.57) | 18.7374 |
| 1990's | 3 (3.57) | 18.2507 |
| 2000's | 30 (35.71) | 29.6817 |
| 2010's | 43 (51.19) | 24.3611 |
| 2020's | 5 (5.95) | 2.80 |
| Authors | Studies |
|---|---|
| Chi, DM; Hamel, E; Ho, HH; Shahrik, LK | 1 |
| Hillenbrand, P; Sherlock, S | 1 |
| Della Marchina, MM; Renzi, G; Serofilli, S | 1 |
| Karasawa, A; Kishibayashi, N; Suzuki, M; Tomaru, A | 1 |
| Matsumori, A; Nose, Y; Ono, K; Sasayama, S; Sato, Y; Shioi, T | 1 |
| Fredholm, BB; Lindström, K | 1 |
| Avendaño, C; Corzo-Suárez, R; Espada, M; Gago, F; García-Granda, S; Martín-Santamaría, S; Rzepa, HS | 1 |
| Daud, A; Munster, P; Spriggs, DR | 1 |
| Bouregeois, NM; Corbett, TH; Crantz, B; Hazeldine, ST; Horwitz, JP; Kushner, J; Palomino, E; Polin, L; White, K | 1 |
| Bailly, C; Lansiaux, A | 1 |
| Almási, J; Hermecz, I; Kökösi, J; Podányi, B | 1 |
| Goldman, B | 1 |
| Shiotsu, Y | 1 |
| Capriotti, T | 1 |
| Hussar, DA | 1 |
| Kaplow, R | 1 |
| Edelman, MJ | 1 |
| Masuda, N; Yanase, N; Yokoba, M | 1 |
| Laurie, SA; Licitra, L | 1 |
| Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H | 1 |
| Auberger, J; Hilbe, W; Loeffler-Ragg, J; Wurzer, W | 1 |
| Sanders, PW; Ying, WZ; Zhang, HG | 1 |
| An, J; Rettig, MB | 1 |
| Hatake, K | 1 |
| Ling, YH; Perez-Soler, R; Piperdi, B | 1 |
| Caldara, A; Graiff, C; Mandarà, M; Pedersini, R; Sava, T; Vattemi, E | 1 |
| Berrino, L; Cascone, T; Ciardiello, F; Heymach, JV; Kim, WY; Lee, HY; Morelli, MP; Morgillo, F; Pepe, S; Rodolico, G; Tortora, G | 1 |
| Kimpe, M; Nuyts, S; Prenen, H | 1 |
| Ahn, KS; Bae, EK; Kim, BK; Kim, BS; Lee, YY; Park, J; Yoon, SS | 1 |
| Cusack, JC; Houston, M; Liu, R; Ljungman, D; Palladino, MA; Sloss, CM; Wang, F; Xia, L | 1 |
| Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP | 1 |
| Brattain, MG; Hauser, J; Hu, YP; Humphrey, LE; Li, W; Panasiewicz, M; Patil, SB | 1 |
| Barr, S; Brown, E; Buck, E; Epstein, D; Eyzaguirre, A; Gibson, NW; Haley, JD; Iwata, KK; Ji, QS; Miglarese, M; Mulvihill, M; O'Connor, M; Pachter, J; Rosenfeld-Franklin, M; Thomson, S; Yao, Y | 1 |
| Adachii, M; Ando, K; Hirose, T; Hosaka, T; Inoue, F; Ishida, H; Kadofuku, T; Kanome, T; Kusumoto, S; Ohmori, T; Ohnishi, T; Okuda, K; Saijo, N; Shirai, T; Sugiyama, T; Yamaoka, T | 1 |
| Bodkin, D; Chiappori, A; Eton, O; Favis, R; Fenton, D; Halmos, B; Hirsh, V; Liu, H; Lynch, TJ; Middleman, EL; Shepherd, FA; Trepicchio, WL | 1 |
| Chen, Z; Ding, WB; Lou, YJ; Ye, ZQ; Yu, YP; Zhang, YD | 1 |
| Bonde, CG; Gaikwad, NJ; Peepliwal, A | 1 |
| Bakthavatchalam, R; Blum, CA; Boyce, S; Brielmann, H; Burnaby-Davies, N; Caldwell, T; Capitosti, S; Chenard, BL; Conley, R; Cortright, D; Crandall, M; De Lombaert, S; Hodgetts, KJ; Jones, AB; Kershaw, MT; Krause, JE; Martin, WJ; Mason, G; Matson, D; Murphy, BA; Perrett, H; Rycroft, W; Zheng, X | 1 |
| Cascone, T; Ciardiello, F; D'Aiuto, E; De Palma, R; De Vita, F; Martinelli, E; Morgillo, F; Orditura, M; Troiani, T | 1 |
| Scheen, AJ | 2 |
| Luo, J; Ma, C; Niu, X; Shao, Z; Shen, K | 1 |
| Gerich, J | 1 |
| Bota, DA; Gong, X; Linskey, ME; Schwartz, PH | 1 |
| Bourdel-Marchasson, I; Dejager, S; Schweizer, A | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Curtit, E; Mansi, L; Viel, E; Vignot, S | 1 |
| Jermendy, G | 2 |
| Guo, RL; He, KW; Hu, YY | 1 |
| Alter, M; Chaykovska, L; Fuchs, H; Heiden, S; Hocher, B; Klein, T; Rahnenführer, J; Runge, F; von Websky, K | 1 |
| Barrière, J; Janus, N; Launay-Vacher, V; Thariat, J | 1 |
| Buck, E; Desai, V; Epstein, DM; Miglarese, M; Wang, J; Zhao, H | 1 |
| Brown, S; Cosulich, SC; Crafter, C; Davies, BR; Dudley, P; Fairley, G; Faulder, P; Fillery, S; Greenwood, H; Hawkins, J; James, M; Johnson, K; Kettle, JG; Lane, CD; Pass, M; Pink, JH; Plant, H | 1 |
| Edwards, KL; Irons, BK; Stapleton, MR; Weis, JM | 1 |
| Ishikawa, M; Yamada, Y | 1 |
| Bakris, GL; Flynn, C | 1 |
| Andriamanana, I; Duretz, B; Gana, I; Hulin, A | 1 |
| Cassidy, J; Hochster, H | 1 |
| Cohen, D | 1 |
| Ardestani, A; Dharmadhikari, G; Kerr-Conte, J; Klein, T; Laue, S; Maedler, K; Pattou, F; Schumann, DM; Shah, P | 1 |
| Charbonnel, B; Dejager, S; Schweizer, A | 1 |
| Chen, SS; Falchook, G; Fok, JY; Fu, S; Heymach, J; Hong, D; Janku, F; Kurzrock, R; Naing, A; Piha-Paul, S; Stephen, B; Tsimberidou, AM; Wheler, J | 1 |
| Baska, F; Breza, N; Kékesi, L; Kéri, G; Németh, G; Őrfi, L; Pató, J; Sipos, A | 1 |
| Chen, CH; Chen, JY; Chen, WS; Chen, YJ; Chien, PH; Hsia, TC; Huang, WC; Liu, SH; Shih, CY; Tu, CY; Wei, YL; Yeh, MH; Yu, MC; Yu, YL | 1 |
| Tibaldi, JM | 1 |
| Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O | 1 |
| Athyros, VG; Elisaf, MS; Filippatos, TD | 1 |
| Abujamra, AL; Alemar, B; Ashton-Prolla, P; de Farias, CB; Giacomazzi, J; Hainaut, P; Hautefeuille, A; Izetti, P; Lenz, G; Osvaldt, AB; Roesler, R; Schwartsmann, G | 1 |
| El-Shentenawy, A; Mohammed, AA | 1 |
| Jin, D; Sakonjo, H; Takai, S | 1 |
| Cui, A; Hou, J; Hua, H; Jiang, Y; Luo, T; Song, P | 1 |
| Boros, S; Breza, N; Dancsó, A; Greff, Z; Hegymegi-Barakonyi, B; Illyés, E; Kékesi, L; Kéri, G; Nemes, Z; Németh, G; Őrfi, L; Pató, J; Sipos, A | 1 |
| Agdauletova, S; Daiber, A; Hausding, M; Klein, T; Kröller-Schön, S; Li, H; Mader, M; Mikhed, Y; Münzel, T; Oelze, M; Pfeffer, A; Schulz, E; Stamm, P; Steven, S; Sudowe, S; Welschof, P; Zinßius, E | 1 |
| James, M; Jeong, JH; Lee, Y; Wang, Y; You, M | 1 |
| Atsumi, T; Ishizu, A; Kusunoki, Y; Miyoshi, A; Miyoshi, H; Nakamura, A; Nakazawa, D; Shida, H; Tomaru, U; Yamada, M | 1 |
| Chung, SJ; Kim, MS; Lee, JH; Maeng, HJ; Noh, CK | 1 |
| Brocato, RL; Hooper, JW | 1 |
| Ikeda, Y; Ikeuchi, M; Nakayama, Y; Saito, Y; Yamagishi, A; Yuki, R | 1 |
| Evans, R; Raubo, P; Willis, P | 1 |
| Ang, GCK; Chang, KT; Guccione, E; Hebrard, M; Lee, VK; Leung, JY; Lim, HJ; Pal, A; Pignata, L; Rao, VK; Taneja, R | 1 |
| Ikeda, Y; Nakayama, Y; Saito, Y; Yasutake, R; Yuki, R | 1 |
| Cass, QB; Furlani, IL; Gales, L; Kijjoa, A; Long, S; Oliveira, JM; Oliveira, RV; Pereira, JA; Pinto, MMM; Resende, DISP; Silva, AMS; Sousa, E | 1 |
26 review(s) available for pyrazines and quinazolines
| Article | Year |
|---|---|
New drugs in gynecologic cancer.
Topics: Aminopyridines; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Cisplatin; Female; Gefitinib; Genital Neoplasms, Female; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Organoplatinum Compounds; Paclitaxel; Protein-Tyrosine Kinases; Pyrazines; Quinazolines; Trastuzumab | 2001 |
[Current screening for molecular target therapy of cancer].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gefitinib; Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactones; Mice; Neoplasms; Phthalazines; Piperazines; Piperidines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib | 2003 |
New oncology strategy: molecular targeting of cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Cetuximab; Cysteine Endopeptidases; ErbB Receptors; Gefitinib; Genetics, Medical; Humans; Medical Oncology; Molecular Biology; Multienzyme Complexes; Neoplasms; Neovascularization, Pathologic; Nurse's Role; Oncology Nursing; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Quinazolines; Trastuzumab; Vascular Endothelial Growth Factor A | 2004 |
Innovations in antineoplastic therapy.
Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate | 2005 |
[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Furans; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Pemetrexed; Pyrazines; Pyridines; Quinazolines; Tegafur; Vinblastine; Vinorelbine | 2005 |
Systemic therapy in the palliative management of advanced salivary gland cancers.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; Clinical Trials as Topic; Deoxycytidine; Gemcitabine; Humans; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Pyrazines; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Salivary Ducts; Salivary Gland Neoplasms; Trastuzumab | 2006 |
Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neovascularization, Pathologic; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2006 |
[Breast cancer and Her-2].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Brain Neoplasms; Breast Neoplasms; Clinical Trials as Topic; Drug Design; Drug Therapy, Combination; ErbB Receptors; Female; Gene Targeting; Humans; Lapatinib; Protease Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2007 |
Systemic therapies for recurrent and/or metastatic salivary gland cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Boronic Acids; Bortezomib; Cetuximab; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Trastuzumab | 2008 |
Salivary gland carcinomas: molecular abnormalities as potential therapeutic targets.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Pyrazines; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Signal Transduction; Vascular Endothelial Growth Factor A | 2008 |
Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
DPP-4 inhibitors: what may be the clinical differentiators?
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Energy Intake; Gastric Emptying; Glucagon-Like Peptide 1; Glycated Hemoglobin; Humans; Hyperglycemia; Hypoglycemic Agents; Incretins; Intestinal Mucosa; Linagliptin; Neurons; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2010 |
Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
Topics: Adamantane; Age Factors; Aged; Aging; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Female; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Male; Middle Aged; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Vildagliptin | 2011 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
[EGFR/HER1: a target life].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Cetuximab; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Neoplasm Proteins; Neoplasms; Panitumumab; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; Quinazolines; ras Proteins | 2012 |
[Dipeptidyl-peptidase-4 inhibitors (gliptins): a new class of oral antidiabetic drugs].
Topics: Adamantane; Animals; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Metformin; Nitriles; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Tablets; Treatment Outcome; Triazoles; Vildagliptin | 2011 |
[Incretin-based therapy for treating patients with type 2 diabetes].
Topics: Adamantane; Body Mass Index; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Approval; Drug Therapy, Combination; Exenatide; Gliclazide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Glycated Hemoglobin; Humans; Hungary; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Metformin; Nitriles; Peptides; Pioglitazone; Purines; Pyrazines; Pyrrolidines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Triazoles; Venoms; Vildagliptin | 2011 |
DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.
Topics: Adamantane; Clinical Trials as Topic; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Therapy, Combination; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Linagliptin; Male; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin; Weight Gain | 2012 |
An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
Topics: Adamantane; Blood Glucose; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Female; Glucagon-Like Peptide 1; Humans; Linagliptin; Male; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2012 |
Noninsulin glucose-lowering agents for the treatment of patients on dialysis.
Topics: Adamantane; Biguanides; Diabetic Nephropathies; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Glucagon-Like Peptides; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Linagliptin; Meglumine; Metformin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Dialysis; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Sulfonylurea Compounds; Thiazolidinediones; Treatment Outcome; Triazoles; Uracil; Vildagliptin | 2013 |
New oxaliplatin-based combinations in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Quinazolines; Thiophenes | 2003 |
Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?
Topics: Adamantane; Body Weight; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Disease Progression; Drug Therapy, Combination; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin; Linagliptin; Nitriles; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Renal Insufficiency, Chronic; Sitagliptin Phosphate; Triazoles; Uracil; Vildagliptin | 2013 |
Incorporating incretin-based therapies into clinical practice for patients with type 2 diabetes.
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Linagliptin; Liraglutide; Peptides; Piperidines; Purines; Pyrazines; Quinazolines; Receptors, Glucagon; Sitagliptin Phosphate; Treatment Outcome; Triazoles; Uracil; Venoms; Weight Loss | 2014 |
The pharmacokinetic considerations and adverse effects of DPP-4 inhibitors [corrected].
Topics: Adamantane; Diabetes Mellitus, Type 2; Dipeptides; Dipeptidyl-Peptidase IV Inhibitors; Drug Interactions; Humans; Linagliptin; Nitriles; Piperidines; Piperidones; Purines; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Thiazolidines; Triazoles; Uracil; Vildagliptin | 2014 |
Advanced thyroid cancers: new era of treatment.
Topics: Anilides; Antineoplastic Agents; Boronic Acids; Bortezomib; Cell Differentiation; Cell Proliferation; ErbB Receptors; Genetic Therapy; Histone Deacetylase Inhibitors; Humans; Immunotherapy; Lithium; Molecular Targeted Therapy; Piperidines; Protein Kinase Inhibitors; Pyrazines; Pyridines; Quinazolines; Stilbenes; Thalidomide; Thyroid Neoplasms | 2014 |
Progress on the Prevention and Treatment of Hantavirus Disease.
Topics: Adrenal Cortex Hormones; Amides; Animals; Antiviral Agents; Clinical Trials as Topic; Hantavirus Infections; Hantavirus Pulmonary Syndrome; Hemorrhagic Fever with Renal Syndrome; Humans; Immunotherapy; Lactoferrin; Models, Animal; Nucleosides; Orthohantavirus; Piperidines; Pyrazines; Quinazolines; Recombinant Proteins; Ribavirin; Triazoles; Vaccines, Synthetic; Viral Vaccines | 2019 |
2 trial(s) available for pyrazines and quinazolines
| Article | Year |
|---|---|
A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Pyrazines; Quinazolines; Salvage Therapy; Survival Rate; Treatment Outcome | 2009 |
Revisiting clinical trials using EGFR inhibitor-based regimens in patients with advanced non-small cell lung cancer: a retrospective analysis of an MD Anderson Cancer Center phase I population.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cetuximab; Dasatinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Quinazolines; Retrospective Studies; Sirolimus; Survival; Thiazoles; Treatment Outcome | 2013 |
56 other study(ies) available for pyrazines and quinazolines
| Article | Year |
|---|---|
Tubulin-dependent hydrolysis of guanosine triphosphate as a screening test to identify new antitubulin compounds with potential as antimitotic agents: application to carbamates of aromatic amines.
Topics: Antineoplastic Agents; Benzimidazoles; GTP Phosphohydrolases; Guanosine Triphosphate; Hydrolysis; Mitosis; Nocodazole; Pyrazines; Quinazolines; Structure-Activity Relationship; Tubulin Modulators | 1989 |
Use of metolazone in the treatment of ascites due to liver disease.
Topics: Adult; Ascites; Chlorides; Chronic Disease; Diuretics; Female; Hepatic Encephalopathy; Humans; Hypokalemia; Hyponatremia; Ketones; Liver Diseases; Male; Middle Aged; Nitrogen; Pyrazines; Quinazolines; Spironolactone; Sulfonamides; Uremia | 1971 |
[Diuretic therapy in the aged. A clinical comparison between two diuretic compounds].
Topics: Aged; Amiloride; Diuretics; Drug Combinations; Drug Evaluation; Female; Humans; Hydrochlorothiazide; Hypertension; Male; Pyrazines; Quinazolines; Sulfonamides | 1981 |
Effects of the adenosine A1-receptor antagonist on defecation, small intestinal propulsion and gastric emptying in rats.
Topics: Adamantane; Animals; Bisacodyl; Defecation; Gastric Emptying; Gastrointestinal Motility; Imidazoles; Intestine, Small; Male; Purinergic P1 Receptor Antagonists; Pyrazines; Quinazolines; Rats; Rats, Sprague-Dawley; Triazoles; Xanthines | 1995 |
Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; 3',5'-Cyclic-GMP Phosphodiesterases; 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; 8-Bromo Cyclic Adenosine Monophosphate; Amrinone; Cells, Cultured; Cyclic GMP; Cyclic Nucleotide Phosphodiesterases, Type 3; Cyclic Nucleotide Phosphodiesterases, Type 4; Cyclic Nucleotide Phosphodiesterases, Type 5; Heart Failure; Humans; Interleukin-1; Interleukin-6; Kinetics; Leukocytes, Mononuclear; Lipopolysaccharides; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Piperidines; Pyrazines; Pyridazines; Quinazolines; Quinolines; Tumor Necrosis Factor-alpha | 1996 |
Autoradiographic comparison of the potency of several structurally unrelated adenosine receptor antagonists at adenosine A1 and A(2A) receptors.
Topics: Adenosine; Animals; Autoradiography; Binding, Competitive; Brain; Caffeine; In Vitro Techniques; Male; Phenethylamines; Purinergic P1 Receptor Antagonists; Pyrazines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Purinergic P1; Theophylline; Triazines; Triazoles; Tritium; Xanthines | 1999 |
Diastereoselective reactions in glycine templates containing an ent-ardeemin fragment.
Topics: Alkylation; Chemistry, Organic; Crystallography, X-Ray; Glycine; Magnetic Resonance Spectroscopy; Models, Molecular; Molecular Conformation; Molecular Structure; Piperazines; Pyrazines; Pyrimidinones; Quinazolines; Stereoisomerism | 2002 |
II. Synthesis and biological evaluation of some bioisosteres and congeners of the antitumor agent, 2-(4-[(7-chloro-2-quinoxalinyl)oxy]phenoxy)propionic acid (XK469).
Topics: Animals; Antineoplastic Agents; Benzoxazoles; Drug Screening Assays, Antitumor; Mice; Neoplasm Transplantation; Propionates; Pyrazines; Pyridines; Quinazolines; Quinolines; Quinoxalines; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Triazines; Tumor Cells, Cultured | 2002 |
[Perspectives on the oncologist pharmacopoeia].
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Boronic Acids; Bortezomib; Dioxoles; Indoles; Isoquinolines; Neoplasms; Organoplatinum Compounds; Protease Inhibitors; Pyrazines; Pyrroles; Quinazolines; Sesquiterpenes; Tetrahydroisoquinolines; Trabectedin | 2003 |
[The multidrug resistance modulators heterocondensed quinazolones].
Topics: ATP-Binding Cassette Transporters; Drug Resistance, Multiple; Indicators and Reagents; Models, Molecular; Molecular Structure; Protein Conformation; Pyrazines; Quinazolines; X-Ray Diffraction | 2003 |
Combinations of targeted therapies take aim at multiple pathways.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Boronic Acids; Bortezomib; Clinical Trials as Topic; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Research Design | 2003 |
New drugs 04. Part III.
Topics: Adrenergic alpha-Antagonists; Antibodies, Anti-Idiotypic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antiemetics; Antineoplastic Agents; Aprepitant; Boronic Acids; Bortezomib; Drug Approval; Drug Interactions; Drug Monitoring; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Fluorobenzenes; Glucans; Glucose; Glucosylceramidase; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Icodextrin; Immunosuppressive Agents; Isoquinolines; Morpholines; Nurse's Role; Omalizumab; Palonosetron; Patient Education as Topic; Pyrazines; Pyrimidines; Quinazolines; Quinuclidines; Rosuvastatin Calcium; Sulfonamides | 2004 |
Lung cancer - Second Annual Winter Conference.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Boronic Acids; Bortezomib; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Structure; Paclitaxel; Pyrazines; Quinazolines | 2005 |
[Molecular-targeted therapy for hormone-refractory prostate cancer].
Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bortezomib; Calcitriol; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelin A Receptor Antagonists; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sulfonamides; Thalidomide; Vitamin D | 2006 |
EGF receptor activity modulates apoptosis induced by inhibition of the proteasome of vascular smooth muscle cells.
Topics: Animals; Apoptosis; bcl-Associated Death Protein; Boronic Acids; Bortezomib; Caspases; Cell Proliferation; Cells, Cultured; ErbB Receptors; Mitochondria; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Protease Inhibitors; Proteasome Inhibitors; Protein Processing, Post-Translational; Pyrazines; Quinazolines; Rats; RNA Interference | 2007 |
Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Renal Cell; Cell Cycle; Cell Death; Cell Survival; Drug Administration Schedule; Drug Synergism; ErbB Receptors; Inhibitory Concentration 50; Kidney Neoplasms; NF-kappa B; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines | 2007 |
Schedule-dependent interaction between the proteosome inhibitor bortezomib and the EGFR-TK inhibitor erlotinib in human non-small cell lung cancer cell lines.
Topics: Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Proliferation; Drug Interactions; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protease Inhibitors; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Tumor Cells, Cultured | 2007 |
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Piperidines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Signal Transduction | 2008 |
Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells.
Topics: Antineoplastic Agents; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Extracellular Signal-Regulated MAP Kinases; Genes, Reporter; Humans; Interleukin-6; Interleukin-7; Luciferases; Multiple Myeloma; NF-kappa B; Phosphorylation; Pyrazines; Quinazolines; Signal Transduction; STAT3 Transcription Factor | 2008 |
Proteasome inhibition activates epidermal growth factor receptor (EGFR) and EGFR-independent mitogenic kinase signaling pathways in pancreatic cancer cells.
Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bevacizumab; Blotting, Western; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lactones; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Pyrroles; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2008 |
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Carboplatin; Carmustine; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; Glial Fibrillary Acidic Protein; Glioblastoma; Immunohistochemistry; Indicators and Reagents; Mice; Proteasome Inhibitors; Pyrazines; Quinazolines; Rats; Temozolomide; Tetrazolium Salts; Thiazoles | 2008 |
Heterogeneity of receptor function in colon carcinoma cells determined by cross-talk between type I insulin-like growth factor receptor and epidermal growth factor receptor.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Evaluation, Preclinical; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imidazoles; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Receptor Cross-Talk; Receptor, IGF Type 1; Signal Transduction; Tumor Cells, Cultured | 2008 |
Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Feedback, Physiological; Female; Humans; Imidazoles; Insulin Receptor Substrate Proteins; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasms, Experimental; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Receptor, IGF Type 1; Signal Transduction | 2008 |
Combination effect between bortezomib and tumor necrosis factor alpha on gefitinib-resistant non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Pyrazines; Quinazolines; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2009 |
[4, 8-disubstituted-8, 9-dihydro-pyrazine[2,3-g]quinazoline-7(6H)-ketones: a novel class of antitumor agents].
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; K562 Cells; Lung Neoplasms; Molecular Structure; Pyrazines; Quinazolines; Stomach Neoplasms; Structure-Activity Relationship | 2010 |
Synthesis and antimycobacterial activity of azetidine-, quinazoline-, and triazolo-thiadiazole-containing pyrazines.
Topics: Antitubercular Agents; Azetidines; Cell Wall; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Permeability; Pyrazines; Quinazolines; Structure-Activity Relationship; Thiadiazoles; Thiazoles | 2010 |
Discovery of novel 6,6-heterocycles as transient receptor potential vanilloid (TRPV1) antagonists.
Topics: Analgesics; Animals; Biological Availability; Capsaicin; Chlorocebus aethiops; COS Cells; Hot Temperature; Humans; Hyperalgesia; In Vitro Techniques; Inflammation; Microsomes, Liver; Naphthyridines; Pain; Pyrazines; Pyridines; Pyrimidines; Quinazolines; Quinolines; Rats; Structure-Activity Relationship; TRPV Cation Channels | 2010 |
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2011 |
Combined effects of lapatinib and bortezomib in human epidermal receptor 2 (HER2)-overexpressing breast cancer cells and activity of bortezomib against lapatinib-resistant breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Breast Neoplasms; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Intracellular Signaling Peptides and Proteins; Lapatinib; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Receptor, ErbB-2 | 2010 |
Neural stem/progenitors and glioma stem-like cells have differential sensitivity to chemotherapy.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cisplatin; Dacarbazine; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Glioma; Humans; Neoplastic Stem Cells; Neural Stem Cells; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Temozolomide | 2011 |
Six alkaloids inhibit secretion of IL-1α, TXB(2), ET-1 and E-selectin in LPS-induced endothelial cells.
Topics: Alkaloids; Animals; Anti-Inflammatory Agents; Benzylisoquinolines; Cells, Cultured; Down-Regulation; Drugs, Chinese Herbal; E-Selectin; Endothelin-1; Endothelium, Vascular; Evodia; Humans; Interleukin-1alpha; Lipopolysaccharides; Morphinans; Proline; Pyrazines; Quinazolines; Quinolizines; Swine; Thromboxane B2 | 2012 |
Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy.
Topics: Animals; Area Under Curve; Cardiomyopathies; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Gene Expression Regulation; Glomerular Filtration Rate; Glucagon-Like Peptide 1; Heart; Humans; Kidney Failure, Chronic; Linagliptin; Myocardium; Natriuretic Peptide, Brain; Nephrectomy; Piperidines; Purines; Pyrazines; Quinazolines; Rats; Reverse Transcriptase Polymerase Chain Reaction; Sitagliptin Phosphate; Triazoles; Uracil; Uremia | 2011 |
[Renal tolerance of targeted therapies].
Topics: Antibodies, Monoclonal; Benzenesulfonates; Boronic Acids; Bortezomib; Erlotinib Hydrochloride; Glomerulonephritis; Humans; Indoles; Kidney; Kidney Tubules; Lapatinib; Molecular Targeted Therapy; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrazines; Pyridines; Pyrroles; Quinazolines; Sirolimus; Sorafenib; Sunitinib | 2012 |
Epithelial-mesenchymal transition predicts sensitivity to the dual IGF-1R/IR inhibitor OSI-906 in hepatocellular carcinoma cell lines.
Topics: Blotting, Western; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Synergism; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gene Expression Regulation, Neoplastic; Hep G2 Cells; Humans; Imidazoles; Insulin-Like Growth Factor II; Liver Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Receptor, IGF Type 1; Receptor, Insulin; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2012 |
Diverse heterocyclic scaffolds as allosteric inhibitors of AKT.
Topics: Allosteric Regulation; Animals; Biological Availability; Biomarkers; Cell Line, Tumor; Drug Screening Assays, Antitumor; Heterocyclic Compounds, 3-Ring; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Mice; Mice, Nude; Models, Molecular; Neoplasm Transplantation; Proto-Oncogene Proteins c-akt; Pyrazines; Pyrazoles; Pyridazines; Pyridines; Quinazolines; Rats; Structure-Activity Relationship; Transplantation, Heterologous | 2012 |
[Therapeutic use and adverse events of incretin-related drugs].
Topics: Adamantane; Aged; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Exenatide; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Incretins; Linagliptin; Liraglutide; Nitriles; Peptides; Piperidines; Purines; Pyrazines; Pyrrolidines; Quinazolines; Sitagliptin Phosphate; Triazoles; Uracil; Venoms; Vildagliptin | 2012 |
Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS.
Topics: Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Chromatography, Liquid; Dasatinib; Erlotinib Hydrochloride; Humans; Imatinib Mesylate; Indoles; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Reproducibility of Results; Sorafenib; Sunitinib; Tandem Mass Spectrometry; Thiazoles | 2013 |
Reports of pancreatitis are 20-30 times more likely with GLP-1 drugs, analysis finds.
Topics: Adamantane; Diabetes Mellitus; Dipeptides; Glucagon-Like Peptide 1; Humans; Hypoglycemic Agents; Linagliptin; Pancreatitis; Purines; Pyrazines; Quinazolines; Sitagliptin Phosphate; Triazoles; United States | 2013 |
The DPP-4 inhibitor linagliptin restores β-cell function and survival in human isolated islets through GLP-1 stabilization.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Cell Survival; Cytokines; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Drug Inverse Agonism; Glucagon-Like Peptide 1; Humans; Insulin; Insulin Secretion; Insulin-Secreting Cells; Interleukin 1 Receptor Antagonist Protein; Interleukin-1beta; Linagliptin; Palmitic Acid; Peptide Fragments; Protein Stability; Purines; Pyrazines; Quinazolines; Recombinant Proteins; Sitagliptin Phosphate; Tissue Culture Techniques; Triazoles | 2013 |
Synthesis and biological evaluation of novel pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction | 2013 |
Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; I-kappa B Kinase; Lapatinib; Mice, SCID; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2013 |
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines | 2013 |
PRIMA-1, a mutant p53 reactivator, induces apoptosis and enhances chemotherapeutic cytotoxicity in pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Boronic Acids; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle; Cell Line, Tumor; Cell Survival; Deoxycytidine; Erlotinib Hydrochloride; Gemcitabine; Humans; Imidazoles; Mutation; Pancreatic Neoplasms; Piperazines; Pyrazines; Quinazolines; RNA, Small Interfering; Tumor Suppressor Protein p53 | 2014 |
EGFR inhibitors may induce tumor stemness.
Topics: Boronic Acids; Bortezomib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Integrin beta3; Neoplastic Stem Cells; Pyrazines; Quinazolines | 2014 |
Significance of vascular dipeptidyl peptidase-4 inhibition on vascular protection in Zucker diabetic fatty rats.
Topics: Animals; Atherosclerosis; Blood Glucose; Carotid Arteries; Chemokine CCL2; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Gene Expression; Glucose Tolerance Test; In Vitro Techniques; Insulin; Linagliptin; Malondialdehyde; NADPH Oxidases; Purines; Pyrazines; Quinazolines; Rats, Zucker; Sitagliptin Phosphate; Triazoles; Vasodilation | 2014 |
Reactive oxygen species-mediated activation of the Src-epidermal growth factor receptor-Akt signaling cascade prevents bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Reactive Oxygen Species; Signal Transduction; src-Family Kinases | 2015 |
[Pyrido[2,3-b]pyrazines inhibiting both erlotinib-sensitive and erlotinib-resistant cell lines, and their preparation via regioselective condensation reaction].
Topics: Antineoplastic Agents; Biochemistry; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Protein Kinase Inhibitors; Pyrazines; Pyridines; Quinazolines; Structure-Activity Relationship | 2014 |
Gliptin and GLP-1 analog treatment improves survival and vascular inflammation/dysfunction in animals with lipopolysaccharide-induced endotoxemia.
Topics: Animals; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, Animal; Endotoxemia; Glucagon-Like Peptide 1; Inflammation; Linagliptin; Lipopolysaccharides; Liraglutide; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Oxidative Stress; Purines; Pyrazines; Quinazolines; Rats; Rats, Wistar; Real-Time Polymerase Chain Reaction; Sitagliptin Phosphate; Triazoles | 2015 |
Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.
Topics: Afatinib; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lung Neoplasms; Mice; Mutation; Pyrazines; Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
Circulating Neutrophil Extracellular Trap Levels in Well-Controlled Type 2 Diabetes and Pathway Involved in Their Formation Induced by High-Dose Glucose.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; DNA; Dose-Response Relationship, Drug; Extracellular Traps; Glucose; Humans; Hypoglycemic Agents; Middle Aged; Neutrophils; Peroxidase; Polymers; Pyrazines; Pyrroles; Quinazolines; Risk Factors; Spiro Compounds; Time Factors | 2016 |
Simultaneous quantification of volitinib and gefitinib in rat plasma by HPLC-MS/MS for application to a pharmacokinetic study in rats.
Topics: Animals; Chromatography, High Pressure Liquid; Gefitinib; Pyrazines; Quinazolines; Rats; Tandem Mass Spectrometry; Triazines | 2017 |
Targeting Insulin-Like Growth Factor 1 Receptor Delays M-Phase Progression and Synergizes with Aurora B Inhibition to Suppress Cell Proliferation.
Topics: Apoptosis; Aurora Kinase B; Benzamides; Cell Differentiation; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Gene Expression Regulation, Neoplastic; HeLa Cells; Humans; Imidazoles; Pyrazines; Pyrimidines; Pyrroles; Quinazolines; Receptor, IGF Type 1; Transcription, Genetic | 2020 |
The discovery and evaluation of 3-amino-2(1H)-pyrazinones as a novel series of selective p38α MAP kinase inhibitors.
Topics: Administration, Inhalation; Alkanes; Amines; Animals; Anti-Inflammatory Agents; Benzamides; Dogs; Drug Evaluation, Preclinical; Humans; Inflammation; Mitogen-Activated Protein Kinase 14; Models, Molecular; Protein Kinase Inhibitors; Pulmonary Disease, Chronic Obstructive; Pyrazines; Quinazolines; Rats; Structure-Activity Relationship | 2020 |
EHMT2 epigenetically suppresses Wnt signaling and is a potential target in embryonal rhabdomyosarcoma.
Topics: Animals; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Dimethyl Sulfoxide; Epigenesis, Genetic; Gene Expression Regulation, Developmental; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Histocompatibility Antigens; Histone-Lysine N-Methyltransferase; Humans; Mice; Mice, Nude; Puromycin; Pyrazines; Pyridines; Quinazolines; Rhabdomyosarcoma, Embryonal; RNA Interference; Wnt Signaling Pathway | 2020 |
Combination Treatment of OSI-906 with Aurora B Inhibitor Reduces Cell Viability via Cyclin B1 Degradation-Induced Mitotic Slippage.
Topics: Aurora Kinase B; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin B1; Dose-Response Relationship, Drug; Humans; Imidazoles; Lung Neoplasms; Mitosis; Protein Kinase Inhibitors; Proteolysis; Pyrazines; Quinazolines; Receptor, IGF Type 1 | 2021 |
Determination of the Absolute Configuration of Bioactive Indole-Containing Pyrazino[2,1-
Topics: Anti-Bacterial Agents; Biological Products; Chromatography, High Pressure Liquid; Circular Dichroism; Crystallography, X-Ray; Fungi; Humans; Indoles; Mass Spectrometry; Metabolome; Molecular Structure; Pyrazines; Quinazolines; Stereoisomerism | 2021 |